Antithrombotic and Hemorrhagic Effects of DX-9065a, a Direct and Selective Factor Xa Inhibitor: Comparison with a Direct Thrombin Inhibitor and Antithrombin Ill-Dependent Anticoagulants
- 1 June 1997
- journal article
- review article
- Published by Georg Thieme Verlag KG in Thrombosis and Haemostasis
- Vol. 78 (05), 1366-1371
- https://doi.org/10.1055/s-0038-1665413
Abstract
(+)-2S-2-[4-[[(3S)-l-acetimidoyl-3- pyrrolidinyl]oxy]phenyl]-3-[7-amidino-2-naphthyl]propanoic acid hydrochloride pentahydrate (DX- 9065a) is an antithrombin III (AT III)-independent and selective inhibitor of activated blood coagulation factor X (FXa). The aim of the present study was to compare the antithrombotic and hemorrhagic effects of DX-9065a with a direct thrombin inhibitor and AT Ill-dependent anticoagulants in rat models of thrombosis and bleeding. Rats were administered intravenously DX-9065a (0.1-1 mg/kg/h), argatroban (0.1-1 mg/k/h), low molecular weight heparin (25-100 anti- XaU/kg/h), unfractionated heparin (25-100 anti-XaU/kg/h) or Orgaran (30-300 anti-XaU/kg/h) for 1 h. DX-9065a dose-dependently inhibited both thrombus formation and elevation in plasma thrombin-AT III complex (TAT) level in a copper wire-inserted arteriovenous (AV) shunt model in rats. The dose required for 50% inhibition of thrombus formation was 0.27 mg/kg/h. DX-9065a did not prolong transection bleeding time up to 7.78 mg/kg/h. Argatroban and AT Ill-dependent anticoagulants also inhibited both thrombus formation and TAT elevation, but prolonged bleeding time at a slightly higher dose than the effective dose. These results suggest that direct and selective inhibition of factor Xa by DX-9065a is preferable for the treatment of thrombosis in the aspect of lack of compromising primary hemostasis.Keywords
This publication has 13 references indexed in Scilit:
- New Antithrombotic Strategies for Resistant Thrombotic ProcessesThe Journal of Clinical Pharmacology, 1994
- Selective factor Xa inhibition by recombinant antistasin prevents vascular graft thrombosis in baboons.Arteriosclerosis and Thrombosis: A Journal of Vascular Biology, 1992
- Antithrombotic effects of synthetic peptides targeting various functional domains of thrombin.Proceedings of the National Academy of Sciences, 1992
- Orgaran (Org 10172): Its Pharmacological Profile in Experimental ModelsPathophysiology of Haemostasis and Thrombosis, 1992
- Antithrombotic efficacy of recombinant tick anticoagulant peptide. A potent inhibitor of coagulation factor Xa in a primate model of arterial thrombosis.Circulation, 1991
- Effect of ticlopidine and other antithrombotics on the venous thrombosis induced by endothelial damage of jugular vein in ratsThrombosis Research, 1991
- Prevention of platelet-rich arterial thrombosis by selective thrombin inhibition.Circulation, 1989
- Thrombin is an important mediator of platelet aggregation in stenosed canine coronary arteries with endothelial injury.JCI Insight, 1989
- Interruption of acute platelet-dependent thrombosis by the synthetic antithrombin D-phenylalanyl-L-prolyl-L-arginyl chloromethyl ketone.Proceedings of the National Academy of Sciences, 1988
- A novel anti-thrombotic heparinoid (ORG 10172) devoid of bleeding inducing capacity: A survey of its pharmacological properties in experimental animal modelsThrombosis Research, 1982